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Abstract – The recommendations for clinical research in developing countries were published in 2007 and the present article
deals with issues which were not initially raised or discussed in depth. In particular, we discuss specific questions linked to
trials conducted in developing countries with regard to informed consent, research project review by two ethics committees,
standards of care, management of biological samples, study follow-up committees, notification of Serious Adverse Events,
paediatric trials, and Contract Research Organizations.
This article follows an initial publication in Thérapie [1] on
the subject of clinical research in developing countries. The latter
publication raised the following questions: 1) the parallel review
of projects by ethics committees in the “Northern” country spon-
soring the study and in the “Southern” country where the research
is to be conducted, 2) the role of the independent committee in
the monitoring of the study, 3) the notification of serious adverse
events, and 4) post-trial commitments. The present article sum-
marizes the development of certain themes that were not initially
discussed in depth. Our objective is to propose for each of these
themes concrete recommendations for guaranteeing both the sci-
entific validity of trials conducted in developing countries and the
respect of universal ethical rules. The general framework of dis-
cussions was that of clinical trials carried out by a sponsor from a
(“Northern”) industrialised country in a (“Southern”) developing
country.
1. Introduction
Scientific and ethical requirements for the conduct of clin-
ical trials are identical throughout the world and established by
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international guidelines, and primarily the Good Clinical Practice
guidelines. [2] Within this fundamental framework, it is sometimes
necessary to adapt practices in order to respond to needs and re-
alities in developing countries. For the clinician or the investiga-
tor, populations called upon in developing countries often corre-
spond to the definition of “vulnerable populations” as defined by
the Recommendations of the Council for International Organiza-
tions of Medical Sciences (CIOMS). [3]
2. Parallel ethics reviews
The 2006 Giens Round Table recommended that France
adopt international recommendations[3] requiring that projects
conducted in the South by sponsors from the North be reviewed by
two ethics committees: a local committee (where the study is to be
carried out) and a committee in the country of the sponsoring or-
ganization in the North. In 2007, despite the positions taken by the
National Consultative Ethics Committee (Comité Consultatif Na-
tional d’Ethique), [4,5] French legislation – dedicated to protect in-
dividuals taking part in trials in France – did not foresee that Com-
mittees for the Protection of Individuals (Comités de Protection
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des Personnes) pronounce themselves on trials conducted outside
of France.
The 2007 Round Table confirmed the importance of present-
ing protocols to two committees so as to review the project in-
dependently albeit in a complementary fashion. If materially pos-
sible, it was deemed advisable that the sponsor first obtain the
opinion of the Northern Committee, in order to be sure that the
rules of their own country are respected before submitting it to the
Southern Committee. A modification of the European Directive
on Clinical Trials [6] could provide an opportunity for introduc-
ing throughout the EU the notion of parallel ethics reviews, while
leaving each country free to decide on the specific modalities of
its application. In France, the composition and functioning of the
existing Committees for the Protection of Individuals would al-
low them to give consultative opinions on projects conducted in
the South without increasing the complexity of existing systems.
3. Informed consent
Free and informed consent of individuals participating in tri-
als is one of the fundamental cornerstones of ethics in clinical
research. The principle of individual consent devoid of constraint
and underpinned by clear and correctly documented information
applies both to developing and industrialised countries. [1] In the
North as in the South, problems arise regarding the pertinence
of information given to patients. When considering the partic-
ular context of developing countries, a certain number of texts
provide recommendations concerning informed consent such as
the UNESCO (United Nations Educationnal, Scientific and Cul-
tural Organisation) Universal Declaration[7] on Bioethics and Hu-
man Rights and the WHO-TDR Recommendations (World Health
Organisation - Special Programme for Research and Training in
Tropical Diseases). [8] Needless to say, large differences can exist
depending on country and culture, on whether trials are to be con-
ducted in urban or rural settings, etc. It should be further stressed
that in developing countries the patient is usually expected to pay
direct health care costs. Thus from the patient’s point of view,
inclusion in a clinical trial may represent (or be perceived as) the
sole option for having access to appropriate care. Freedom of con-
sent must thus be considered in the light of this fact.
The Round Table felt that it was fundamental that the condi-
tions in which the consent of patients in developing countries was
obtained be precisely documented and where necessary reconsti-
tuted in hindsight. In order to do so, it was recommended that the
study protocol specify as minutely as possible the way the consent
is to be solicited and obtained given the particular local context
of each study. In the North, a “standard” paragraph of the pro-
tocol concerning information and acquisition of consent may be
acceptable, because the principles and modalities thereof entered
into common practice many years go and the fundamental princi-
ples are coherent with Western culture. However, we believe that
a standard paragraph is insufficient for developing countries be-
cause it does not take into account the reality of the process set up
for informing patients and gathering their consent. For instance it
will be important to specify in the protocol which languages will
be used for written documents and oral explanations, how illit-
erate persons will be informed and their consent obtained, how
possible witnesses will be chosen and classified, whether an ac-
tion of community information will be organised, whether meth-
ods will be applied to evaluate acceptance, how children’s consent
will be obtained, etc. This information in addition to precise writ-
ten documentation will allow study monitors to have a clearer idea
of the authenticity of informed consent and respond to possible
queries after the trial. With regard to informed consent, a paral-
lel North-South ethics review is particularly important in order to
avoid “double standard”. In case of persisting disagreement be-
tween committees, the opinion of the Southern Committee shall
prevail.
4. Standard of care
At the end of 1990s a controversy arose over the notion of
standard of care regarding the use of placebo in trials of antiretro-
viral drugs for preventing mother-to-child transmission of HIV in
Africa. [9] The efficacy of these treatments had been demonstrated
in the North, but the duration and complexity of treatment as well
as the anticipated costs linked to care made the use of such drugs
highly complex if not impossible in the South. Certain scientists
had deemed it necessary to compare a short oral treatment with
a placebo. The question was then raised as to whether the stan-
dard of care applied to patients in a research setting should be the
best available standard worldwide or locally. The Helsinki Decla-
ration was revised in 2000 and stated that the comparison of a new
method must be conducted using “the best current prophylactic,
diagnostic, and therapeutic methods”. [10] This revision gave rise
to many publications in which the supporters of a single universal
standard opposed to the notion of “double standard” argued with
those who contested such an approach in the name of feasibility
of trials and their pertinence in the case of poor populations in
developing countries who would not in any case have access to
such standards. By 2002, the Nuffield Council of Bioethics in the
United Kingdom had proposed a way of defining circumstances
in which it was conceivable not to respect the “universal stan-
dard”. [11]
The Round Table supported the approach proposed by Wen-
del et al. of the National Institutes of Health (NIH) Bioethics
Center [12] according to which the best available standard should
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be used while accepting exceptions to the rule on four condi-
tions: one, there must be a scientific justification for using a “local
standard”; two, the question posed must be pertinent for the lo-
cal population; three, the community must be expected to obtain
sufficient benefit and, lastly, the risk-benefit must be acceptable
for subjects participating in the study. The Round Table wished
to see a fifth condition added, namely the methodology used must
have been demonstrated to provide scientific answers to the ques-
tion posed. The limits of studies of non-inferiority in the case of
comparison to “local standards” were stressed. [13–17] Indeed the
demonstration of non-inferiority does not provide proof of true
efficacy of an experimental treatment if the chosen comparator is
not optimal. In the case of comparison with a “local standard”, a
trial seeking to demonstrate the superiority of the treatment un-
der investigation rather than its equivalence might be preferred,
especially if available data suggest that the local treatment does
not have optimal efficacy. The ideal trial is to compare the treat-
ment under investigation with both the “universal standard” and
the “local standard”. It is essential that when the rule of “univer-
sal standard” is not applied, this be done in total transparency in
accordance with the ethics and regulatory authorities and that all
decisions be clearly documented.
5. Management of biological samples
The issue of biological samples collected in the course of
clinical investigations is complex and the same questions arise in
the North and in the South regarding the property of these sam-
ples, their use to ends not initially foreseen, the patentability of
certain discoveries, etc. The confidentiality of medical informa-
tion as well as the patients’ right to access information which con-
cerns them and to give their opinion on its use must be respected.
Developing countries may legitimately wish to acquire new tech-
niques rather than let their samples go and be analysed abroad
without any benefit for themselves. Following the 1992 declara-
tion of the Convention of Biological Diversity, the so-called “Rio
Convention”, [18] more and more developing countries have be-
come aware of the risk of having their samples kept in the North
and used without their knowledge and possibly to mercantile ends.
They have thus taken measures to oppose the exportation of such
samples. In 2007, a controversy arose concerning the exportation
of influenza virus strains in Indonesia [19] and the Russian customs
service on its end temporarily blocked the exportation of biologi-
cal samples as of May 2007. New recommendations have recently
been adopted by OECD (Organisation of Economic Cooperative
Development) countries concerning the management of biologi-
cal samples. [20] These recommendations may provide appropriate
means for the storage and quality management of biological sam-
ples collected in the South.
Recommendations of the Round Table
It is important to distinguish among three different types of
situations: 1) collection of biological samples constituted for the
sole purpose of research, 2) complementary analyses foreseen by
the protocol but to be conducted after the actual research, and
3) changes in the final purpose of these complementary analyses
post-hoc. The study protocol establishes the conditions in which
the samples are conducted, preserved, and analysed. It may also
include - along with the consent form - a clause regarding the
possibility of conducting investigations complementary to those
first foreseen if they are necessary for the pursuit of the initial
study goal. In such conditions, the protocol must specify that the
authorization of the ethics committee will be sought and, when
materially possible, that patients will be informed. The situation
is more complicated when investigators wish to use the samples
for objectives entirely distinct from those initially foreseen by the
study (change of final purpose). It does not seem possible to rec-
ommend a single attitude in such circumstances; thus, cases must
be managed individually. Generally speaking, it is important that
the decisions taken not endanger the rights and integrity of the pa-
tients nor the validity of collected samples and that of the trial, for
example by accepting to compromise on the quality of conditions
of preservation, transportation or analysis. When questions arise
concerning the aftermath of a collection of samples preserved in
the North, it may be appropriate to establish a “databank commit-
tee” composed of institutions both from the North and the South
who will oversee the possible use of the samples stored in the
North, perhaps many years later. Furthermore, in order to respond
both to developing countries’ wish to acquire new technologies
and to that of guaranteeing the best possible quality of analyses,
we recommend that samples be exported to a central laboratory in
the North for the needs of the study, while helping the develop-
ing country to acquire expertise to be used afterwards. Finally, the
group discussed the question of biological tests with possible con-
sequences in terms of confidentiality and care of newly diagnosed
patients, such as HIV or viral hepatitis tests. These questions can
arise when one is seeking to ensure the protection of persons ma-
nipulating biological samples or in order to study concomitant dis-
ease. Whatever the motivations, the Round Table concluded that
such tests could be conducted only when a) prior information of
and consent from patients could be guaranteed and b) patient care
by a national programme not solely dependent of the study spon-
sor is ensured.
6. Monitoring committees
The 2006 Round Table had recommended that clinical trials
be monitored by two committees: 1) a Scientific Committee, i.e. a
structure of the sponsor in charge of conceiving and coordinating
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the study process and 2) an Independent Monitoring Committee
(or Data and Safety Monitoring Board or Data Monitoring Com-
mittee, [DSMB or DMC]). The DSMB must be independent of the
sponsor in order to safeguard the study. It is meant to avoid bias
and methodological errors while contributing to the guarantee of
patient safety. A DSMB is not required for all studies, but it is
necessary when the treatments under investigation present poten-
tial risks in terms of tolerance or inefficacy, when the study con-
cerns a serious disease lacking efficacious treatment, when it takes
place in a context of intense activity of surrounding research and
when it concerns vulnerable populations or individuals in emer-
gency situations.
The present Round Table recommended that, for studies con-
ducted in developing countries, the DSMB should include mem-
bers representing the sponsoring country as well as the country in
which the study is being conducted. It is important to ensure the
independence of the DSMB members with regard to the sponsor
and investigators and their autonomy with regard to local public
health authorities. The DSMB’s work relies on information gath-
ered during the monitoring of the study and thus the quality of data
is crucial if the DSMB is to fulfil its role. Finally, before beginning
the study the practical rules and modalities for the functioning of
the DSMB should be defined: transmission of data, organization
of meetings, documentation of decisions, “confidentiality” with
regard to investigators and promoter, etc. This is nevertheless of-
ten rendered complex owing to material conditions in developing
countries.
7. Notification of Serious Adverse Events (SAE)
The recommendations of the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH)[21] require the sponsor to
inform the health authorities of SAE occurring during clinical tri-
als within a period of 8 to 15 days depending on whether the SAE
implicates or not vital prognosis, as well as to provide an annual
report on the tolerance to the drug under study. The investigators
dealing with the drug under study must also be informed of the oc-
currence of SAE declared in other investigation centres. The 2006
Round Table recognized the difficulty of fulfilling these obliga-
tions because SAE registration and treatment structures are often
lacking in developing countries.
The present Round Table recommended that setting up clini-
cal trials in developing countries provide an opportunity for con-
sulting with local authorities on the information network to be
established for SAE. It is important to collaborate with local au-
thorities before the onset of the study in order to ensure that they
are prepared to receive and manage SAE notifications. In addition
to those documents required by the regulations, it may be appro-
priate to provide summary documents more easily used by the
authorities, such as an annual report on the progress of the study
which would summarize the conclusions of the DSMB reports.
Likewise, the way of informing investigators should be considered
case by case, respecting local and international legal frameworks
in order to provide the most appropriate information possible. The
Round Table stressed the importance that each study engages in
awareness activities and transmission of expertise in drug safety
monitoring to developing country authorities and investigators.
8. Paediatric trials
In the North as in the South, clinical research in paediatrics
raises particular methodological and ethical problems, and iden-
tical (or equivalent) standards must be applied. These questions
are particularly relevant in the South because the vast majority of
clinical trials in infectious diseases conducted in developing coun-
tries involve children. Infectious diseases, essentially tuberculo-
sis, diarrhoeas, malaria, measles, and HIV/AIDS, cause more than
half of premature deaths, usually in children and young adults. [22]
Specifically, problems in the developing world are largely linked
to the economic and social context of many countries which usu-
ally limits the access of children to treatment. In addition, cul-
tural factors sometimes have consequences on the perception of
the importance of child health or notions that are in contradiction
with the Western culture of the child as “king”. Certain children
are particularly vulnerable, such as street children or those totally
marginalized by society or else those living in countries where
access to treatment is possible only through school attendance.
Exemptions when conducting trials in vulnerable populations, for
example in the case of emergency situations or major direct ben-
efit, are justified in very particular situations. Discussions around
this topic did not lead to total consensus among participants. How-
ever, all agreed on the importance of stressing that even in situa-
tions of great impoverishment, the clinical trial cannot provide an
alternative to treatment in face of lack of access to care.
9. Contract Research Organizations
Contract Research Organizations (CRO) are increasingly ac-
tive in developing countries. The term CRO includes companies
or organizations involved in various activities, under the responsi-
bility of the trial sponsor or the organization in charge of drug de-
velopment. They help meet rising needs in terms of recruitment of
patients required by regulation authorities and by the tendency of
many industrial sponsors to externalize clinical research activities.
In addition, they respond to opportunities offered by large emerg-
ing countries and their diversity allows them to adapt to the laws of
supply and demand. Their contribution may be limited to technical
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advice, data analysis, drafting of documents, conduct of clinical
trials, but they may also be asked to manage important parts of the
clinical development of new drugs. Certain CROs employ several
tens of thousands of collaborators throughout the world, whereas
others are implanted in only one country and commission rela-
tively few people. In developing countries, most CROs use local
subcontractors for all or part of their activities. Certain large CROs
have passed agreements with young companies (“start-ups”) in or-
der to lead the development of drugs from phase I all the way to
registration. In certain cases, such conditions may result in CROs
taking on the role of sponsor and the ensuing responsibilities. In-
deed, in developing countries, one may question the role of CROs
if their involvement leads to situations of de facto monopolies
given their implantation in the country, their capacity to recruit,
the development of data management tools which then become
“indispensable” and disproportional with regard to the trial. The
situation of CROs is evolving very rapidly and it has not been pos-
sible to investigate the situation fully. In 2003, their worldwide
involvement concerned 64% of clinical trials from phase I to III,
whereas ten years earlier (1993) it had been only 28%.[23] It ap-
peared of great importance to the Round Table that when trials are
conducted in developing countries together with CROs, a detailed
document be drawn up listing all involved partners, including pos-
sible subcontractors, and specify the roles and responsibilities of
all those concerned in both legal and operational terms.
10. Conclusion
The work conducted during the 2006 and 2007 meetings at
Giens on clinical trials in developing countries showed that the
fundamental principles of scientific validity and respect for ethics
demand identical standards in the North and in the South. The rec-
ommendations issued on particular points are in agreement with
the threefold concern: 1) to respect the specificities of develop-
ing countries, 2) not to impose upon them heavy and unjustified
constraints that might result in penalization, but also 3) not to ac-
cept compromises on essential questions, in particular as regards
vulnerable populations. We realized the difficulty of formulating
general recommendations on the basis of inevitably limited ex-
perience, while avoiding excessive simplification and the risk of
distortion of reality. Developing countries represent an infinite va-
riety of situations in constant evolution. Many of today’s rules of
conduct and requirement measures will perhaps be outdated very
soon. However, it can be reasonably stated that questions arising
during clinical trials can be resolved – while respecting current
regulations – by associating all stakeholders in decision-making
and working in total transparency, both in the South and in the
North.
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